269 related articles for article (PubMed ID: 25790163)
1. Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies.
Lee K; Garg S
Genet Med; 2015 Apr; 17(4):245-52. PubMed ID: 25790163
[TBL] [Abstract][Full Text] [Related]
2. The new landscape of retinal gene therapy.
Ku CA; Pennesi ME
Am J Med Genet C Semin Med Genet; 2020 Sep; 184(3):846-859. PubMed ID: 32888388
[TBL] [Abstract][Full Text] [Related]
3. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
[No Abstract] [Full Text] [Related]
4. Dog models for blinding inherited retinal dystrophies.
Petersen-Jones SM; Komáromy AM
Hum Gene Ther Clin Dev; 2015 Mar; 26(1):15-26. PubMed ID: 25671556
[TBL] [Abstract][Full Text] [Related]
5. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
[TBL] [Abstract][Full Text] [Related]
6. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene.
Chung DC; Bertelsen M; Lorenz B; Pennesi ME; Leroy BP; Hamel CP; Pierce E; Sallum J; Larsen M; Stieger K; Preising M; Weleber R; Yang P; Place E; Liu E; Schaefer G; DiStefano-Pappas J; Elci OU; McCague S; Wellman JA; High KA; Reape KZ
Am J Ophthalmol; 2019 Mar; 199():58-70. PubMed ID: 30268864
[TBL] [Abstract][Full Text] [Related]
7. Emerging Gene Therapy Treatments for Inherited Retinal Diseases.
Bakall B; Hariprasad SM; Klein KA
Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):472-478. PubMed ID: 30021033
[No Abstract] [Full Text] [Related]
8. [Genetic diagnostic testing in inherited retinal dystrophies].
Kohl S; Biskup S
Klin Monbl Augenheilkd; 2013 Mar; 230(3):243-6. PubMed ID: 23208805
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
10. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
Maguire AM; Bennett J; Aleman EM; Leroy BP; Aleman TS
Mol Ther; 2021 Feb; 29(2):442-463. PubMed ID: 33278565
[TBL] [Abstract][Full Text] [Related]
11. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
12. RPE65-related retinal dystrophy: Mutational and phenotypic spectrum in 45 affected patients.
Lopez-Rodriguez R; Lantero E; Blanco-Kelly F; Avila-Fernandez A; Martin Merida I; Del Pozo-Valero M; Perea-Romero I; Zurita O; Jiménez-Rolando B; Swafiri ST; Riveiro-Alvarez R; Trujillo-Tiebas MJ; Carreño Salas E; García-Sandoval B; Corton M; Ayuso C
Exp Eye Res; 2021 Nov; 212():108761. PubMed ID: 34492281
[TBL] [Abstract][Full Text] [Related]
13. [Specific gene therapy for hereditary retinal dystrophies - an update].
Stieger K; Lorenz B
Klin Monbl Augenheilkd; 2014 Mar; 231(3):210-5. PubMed ID: 24327302
[TBL] [Abstract][Full Text] [Related]
14. Extensive genic and allelic heterogeneity underlying inherited retinal dystrophies in Mexican patients molecularly analyzed by next-generation sequencing.
Zenteno JC; García-Montaño LA; Cruz-Aguilar M; Ronquillo J; Rodas-Serrano A; Aguilar-Castul L; Matsui R; Vencedor-Meraz CI; Arce-González R; Graue-Wiechers F; Gutiérrez-Paz M; Urrea-Victoria T; de Dios Cuadras U; Chacón-Camacho OF
Mol Genet Genomic Med; 2020 Jan; 8(1):. PubMed ID: 31736247
[TBL] [Abstract][Full Text] [Related]
15. Frequency of
Kahraman NS; Öner A; Özkul Y; Dündar M
Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
[TBL] [Abstract][Full Text] [Related]
16. Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
Weng CY
Ophthalmol Retina; 2019 May; 3(5):450. PubMed ID: 31044739
[No Abstract] [Full Text] [Related]
17. Retinal dystrophies and gene therapy.
Sundaram V; Moore AT; Ali RR; Bainbridge JW
Eur J Pediatr; 2012 May; 171(5):757-65. PubMed ID: 22080959
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
19. Preserved visual function in retinal dystrophy due to hypomorphic
Hull S; Holder GE; Robson AG; Mukherjee R; Michaelides M; Webster AR; Moore AT
Br J Ophthalmol; 2016 Nov; 100(11):1499-1505. PubMed ID: 26906952
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Modern Technologies on Molecular Diagnostic Success Rates, with a Focus on Inherited Retinal Dystrophy and Hearing Loss.
de Bruijn SE; Fadaie Z; Cremers FPM; Kremer H; Roosing S
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
